Benign prostatic hyperplasia/urinary retention:
Indications for: FLOMAX
Benign prostatic hyperplasia (BPH).
Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate.
Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Severe hepatic impairment. Cataract or glaucoma surgery: do not initiate therapy (possible Intraoperative Floppy Iris Syndrome). Not for use in women.
Do not use with other α-blockers or strong CYP3A4 inhibitors (eg, ketoconazole). Caution with concomitant moderate CYP3A4 inhibitors (eg, erythromycin), moderate or strong CYP2D6 inhibitors (eg, paroxetine, terbinafine), or CYP2D6 poor metabolizers (esp. with tamsulosin >0.4mg/day). Caution with concomitant cimetidine (esp. with tamsulosin >0.4mg/day) or warfarin. Symptomatic hypotension with concomitant PDE5 inhibitors.
Headache, abnormal ejaculation, dizziness, rhinitis, infection, asthenia, back pain, diarrhea, pharyngitis, chest pain, nausea, tooth disorder, blurred vision, cough, somnolence, sinusitis, libido decreased, insomnia; rare: priapism.
Renal (76%), fecal (21%). Half-life: 9–13 hours.
Generic Drug Availability: